TY  - JOUR
AU  - Marín-Candón, Alicia
AU  - Rosso-Fernández, Clara M
AU  - Bustos de Godoy, Natalia
AU  - López-Cerero, Lorena
AU  - Gutiérrez-Gutiérrez, Belén
AU  - López-Cortés, Luis Eduardo
AU  - Barrera Pulido, Lydia
AU  - Borreguero Borreguero, Irene
AU  - León, María José
AU  - Merino, Vicente
AU  - Camean-Fernández, Manuel
AU  - Retamar, Pilar
AU  - Salamanca, Elena
AU  - Pascual, Alvaro
AU  - Rodriguez-Baño, Jesús
AU  - ASTARTÉ Study Group
PY  - 2021
DO  - 10.1136/bmjopen-2021-049481
UR  - https://hdl.handle.net/10668/27611
T2  - BMJ open
AB  - Alternatives to carbapenems are needed in the treatment of third-generation cephalosporin-resistant Enterobacterales (3GCR-E). Temocillin is a suitable candidate, but comparative randomised studies are lacking. The objective is to investigate if...
LA  - en
KW  - bacteriology
KW  - clinical pharmacology
KW  - infection control
KW  - infectious diseases
KW  - microbiology
KW  - Bacteremia
KW  - Cephalosporins
KW  - Clinical Trials, Phase III as Topic
KW  - Enterobacteriaceae
KW  - Humans
KW  - Meropenem
KW  - Multicenter Studies as Topic
KW  - Penicillins
KW  - Pragmatic Clinical Trials as Topic
KW  - Randomized Controlled Trials as Topic
TI  - Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial.
TY  - research article
VL  - 11
ER  -